Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue

D3_OTHDISLYMPHORETANDRETICULOHIST

hematologic disease: A disease involving the hematopoietic system.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — D76 Cause of death: ICD-10 — D76 2 out of 7 registries used, show all original rules.	118
4. Check minimum number of events None	118
5. Include endpoints D3_HAEMOPHAGOLYMPHO D3_HAEMOPHAGOSDR D3_HISTICYTSDROTH	118
6. Filter based on genotype QC (FinnGen only)	118

Control definitions (FinnGen only)

Control exclude: D3_BLOODOTHER

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: D70-D77
Name in latin: Aliqui morbi textus lymphoreticularis et systematis reticulohistiocytici

NAME	D3_OTHDISLYMPHORETANDRETICULOHIST
CONTROL_EXCLUDE	D3_BLOODOTHER
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE	D3_HAEMOPHAGOLYMPHO\|D3_HAEMOPHAGOSDR\|D3_HISTICYTSDROTH
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D76
HD_ICD_9
HD_ICD_8
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D76
COD_ICD_9
COD_ICD_8
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue based on the number of shared cases.

Similar with more cases:

Similar with less cases:

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	896	420	473
Only index persons	719	332	387
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	34.32	35.37	33.34
Only index persons	41.02	42.89	39.42

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	118	55	63
Unadjusted period prevalence (%)	0.02	0.02	0.03
Median age at first event (years)	52.10	52.89	51.41

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
104: Matched controls
1041

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

D76.1

ICD-10 Finland

Haemophagocytic lymphohistiocytosis

+∞

46.4

D76.3

ICD-10 Finland

Other histiocytosis syndromes

+∞

42.7

D76.00

ICD-10 Finland

Eosinophilic granuloma

+∞

31.9

D76.01

ICD-10 Finland

Histiocytosis X (chronic)

+∞

22.7

A49.9

ICD-10 Finland

Bacterial infection, unspecified

14.5

21.9

XW000

NOMESCO Finland

Bone marrow biopsy

31.3

21.4

117

Kela drug reimbursment

Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue

26.8

20.4

H02AB09

ATC

hydrocortisone; systemic

32.7

14.9

GD1UA

NOMESCO Finland

Thorax X-ray examination outside radiological department

7.1

14.6

TNE25

NOMESCO Finland

Drill biopsy of bone marrow, pelvis

86.5

14.0

JN4BD

NOMESCO Finland

Extensive body CT

8.9

13.1

GD1AA

NOMESCO Finland

Thorax X-ray examination

4.9

13.1

307

R50.9

ICD-10 Finland

Fever, unspecified

6.3

12.8

WW500

NOMESCO Finland

Blood transfusion

19.0

12.7

JN3AE

NOMESCO Finland

Abdominal ultrasound examination

5.8

11.5

D69.6

ICD-10 Finland

Thrombocytopenia, unspecified

67.1

10.9

JN4AD

NOMESCO Finland

Body CT examination

11.5

10.9

N17.9

ICD-10 Finland

Acute renal failure, unspecified

14.2

10.8

H02AB06

ATC

prednisolone; systemic

4.1

10.6

318

H02AB02

ATC

dexamethasone; systemic

8.6

10.5

GD1DD

NOMESCO Finland

High resolution CT examination of lungs

10.8

10.0

NK6QA

NOMESCO Finland

Measurement of bone density from tow or more locations with X-ray

13.3

10.0

D64.9

ICD-10 Finland

Anaemia, unspecified

7.9

10.0

J01EE01

ATC

sulfamethoxazole and trimethoprim; systemic

11.7

9.4

A12AX

ATC

Calcium, combinations with vitamin D and/or other drugs

4.1

9.4

169

UGC12

NOMESCO Finland

Flexible bronchoscopy

7.2

9.1

AA1CG

NOMESCO Finland

Extensive MRI examination of brain with high intensity magnet

6.5

9.0

ZX120

NOMESCO Finland

Intravenous

7.1

8.9

TQX10

NOMESCO Finland

Biopsy of skin and subcutaneous tissue

6.0

8.8

GD1PA

NOMESCO Finland

X-ray examination of the lungs in one projection

6.9

8.8

A41.9

ICD-10 Finland

Sepsis, unspecified

14.5

8.7

JN4JR

NOMESCO Finland

Whole body extensive metabolic PET with CT

97.6

8.5

D70.82

ICD-10 Finland

Drug-induced neutropenia

+∞

8.4

D76.2

ICD-10 Finland

Haemophagocytic syndrome, infection-associated

+∞

8.4

D76.0

ICD-10 Finland

Langerhans' cell histiocytosis, not elsewhere classified

+∞

8.4

L03AA02

ATC

filgrastim; parenteral

36.5

8.2

R59.0

ICD-10 Finland

Localized enlarged lymph nodes

13.3

7.8

AA1DG

NOMESCO Finland

Very extensive MRI examination of brain with high intensity magnet

11.3

7.8

FB1BD

NOMESCO Finland

Extensive CT examination of arteria pulmonalis

6.8

7.7

TPX10

NOMESCO Finland

Implantation of vascular injection port

14.9

7.6

GD1QA

NOMESCO Finland

Supine thorax X-ray examination

4.6

7.3

WD105

NOMESCO Finland

Cystostatic therapy of methastized malignancy

9.3

7.1

WD405

NOMESCO Finland

Simple antiboidy therapy of methastized malignancy

18.2

6.9

JN1AE

NOMESCO Finland

Ultrasound examination of upper part of abdomen

5.7

6.8

GD1AD

NOMESCO Finland

Thorax CT examination

9.7

6.8

GD1ED

NOMESCO Finland

Extensive high resolution CT examination of lungs

9.7

6.8

M04AA01

ATC

allopurinol; systemic

4.8

6.6

WD125

NOMESCO Finland

Demanding cystostatic therapy of methastized malignancy

9.1

6.6

DM1AA

NOMESCO Finland

Paranasal sinuses X-ray examination without contrast

15.6

6.5

JN6AD

NOMESCO Finland

CT of torso and neck

74.2

6.5

PJ2AE

NOMESCO Finland

Lymphnode ultrasound examination

28.6

6.3

ZX108

NOMESCO Finland

Inhalation

28.6

6.3

JN6BD

NOMESCO Finland

Extensive CT of torso and neck

28.6

6.3

EN1AD

NOMESCO Finland

CT examination of mouth and soft tissues of neck

+∞

6.3

102

Kela drug reimbursment

Diabetes insipidus

+∞

6.3

Mortality – FinRegistry

↥

Association

Association between endpoint D3_OTHDISLYMPHORETANDRETICULOHIST and mortality.

Females

Parameter	HR [95% CI]	p-value
D3_OTHDISLYMPHORETANDRETICULOHIST	4.294 [2.6, 7.1]	< 0.001
Birth year	0.998 [0.99, 1.01]	0.683

During the follow-up period (1.1.1998 — 31.12.2019), 66 out of 345 females with D3_OTHDISLYMPHORETANDRETICULOHIST died.

Males

Parameter	HR [95% CI]	p-value
D3_OTHDISLYMPHORETANDRETICULOHIST	3.517 [2.18, 5.68]	< 0.001
Birth year	0.99 [0.98, 1.0]	0.029

During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 367 males with D3_OTHDISLYMPHORETANDRETICULOHIST died.

Mortality risk

Mortality risk for people of age

years, who have D3_OTHDISLYMPHORETANDRETICULOHIST.

N-year risk	Females	Males
1	0.342%	0.823%
5	2.472%	4.244%
10	5.771%	10.339%
15	11.403%	19.136%
20	20.89%	30.915%

Relationships between endpoints

↥

Index endpoint: D3_OTHDISLYMPHORETANDRETICULOHIST – Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

Extremity

rg [CI]

Extremity

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints